{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-24-000009","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.005080+00:00","generated_at":"2026-06-07T00:52:56.102302+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rapid Micro Q4 rev ~$6.2-6.4M (+45%); FY rev ~$22.4-22.6M (+30%); cash $95M runway into H2 2026","bullets":["Q4 revenue expected $6.2-6.4M (+45% YoY); FY23 revenue $22.4-22.6M (+30% YoY).","Placed 16 Growth Direct systems in FY23, 6 in Q4; 18 validations completed in FY23.","Cash and investments ~$95M as of Dec 31, 2023; cash runway at least into H2 2026.","Growth Direct selected by Samsung Biologics; systems now placed with 100% of commercial CAR-T manufacturers.","Commercial launch of Growth Direct Rapid Sterility app expected by mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-24-000009","json":"https://secwatch.observer/filing/0001380106-24-000009.json","markdown":"https://secwatch.observer/filing/0001380106-24-000009.md","text":"https://secwatch.observer/filing/0001380106-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010624000009/0001380106-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010624000009/rpid-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:52:56.102302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"722caba41f5aed714d1f0f61b604d7056becff2b","claim":"RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On January 10, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010624000009/0001380106-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}